Free Biopharma Daily Stock Updates - 07/19/21

$XBI $126.14 +0.16%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$RDHL +4.9% RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib. source

Pipeline Updates

$CYDY +4.9% CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials source

$AMRX +0.2% Amneal Receives Approval for Generic TobraDex® source

$ARDX +2.70% Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis source

$ATNX -3.0% Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis. source

$SLS +4.2% Galinpepimut-S Plus Pembrolizumab Shows Early Activity in Advanced Ovarian Cancer . source

$AQST +7.8% Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film. source

$GTHX -5.7% G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer. source

$NMTR +-0.0% 9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity. source

$CPRX +0.70% Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®. source

$ALBO +2.0% Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC). source

$CLSN +6.7% Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer. source

$XERS +0.30% Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe. source

$CYTK +40.4% Cytokinetics Announces Positive Topline Results of Redwood-HCM. source

$CFRX -2.8% ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity. source

$KDMN -6.5% Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK™ (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD). source

$FGEN -4.4% Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform. source

$ATHA +4.6% Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC). source

$CYDY +17.0% CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis. source

$AZN -0.50% Imfinzi approved in China for the treatment of extensive-stage small cell lung cancer. source

$VALN +1.80% Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate. source

$GILD -0.60% New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor. source

$GILD -0.60% Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults. source

Financial Updates

$PLXB +1.70% PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August source

$IMUX -1.8% Immunic, Inc. Announces Closing of $45.0 Million Public Offering source

$CYTK +40.4% Cytokinetics Announces Proposed Public Offering Of Common Stock source

$JAGX +10.7% Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing. source

$BNTX +4.8% BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD. source

---

Posted by FS/JM